Inactive Instrument
Claritas Pharmaceuticals Stock Toronto S.E.
Stocks
KLY
CA1806341071
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 5.37M 3.82M 3.32M 3.1M 2.85M 364M 5.46M 36.5M 14.28M 182M 14.36M 14.04M 601M | P/E 2019 |
-0.74x | P/E 2020 | 0.13x |
|---|---|---|---|---|---|
| Enterprise Value | 6.29M 4.47M 3.89M 3.63M 3.33M 427M 6.4M 42.75M 16.73M 213M 16.82M 16.45M 705M | EV / Sales 2019 |
-
| EV / Sales 2020 | - |
| Free-Float |
99.74% | Yield 2019 * |
-
| Yield 2020 | - |
| 1 day | +11.11% |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CEO | Chief Executive Officer | 76 | 2017-06-20 |
Victoria Rudman
DFI | Director of Finance/CFO | 58 | 2018-06-28 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CHM | Chairman | 76 | 2021-03-17 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +11.11% | -.--% | - | - | 37 | |
| -0.36% | +2.23% | -2.06% | +12.54% | 48.53B | |
| -2.71% | -3.58% | +398.09% | +456.59% | 39.87B | |
| -0.71% | +12.17% | +27.90% | +6.51% | 38.68B | |
| -0.71% | -3.72% | +4.94% | +65.34% | 35.13B | |
| -2.41% | +2.59% | +11.68% | +41.16% | 29.79B | |
| -0.66% | -4.67% | +35.50% | +124.56% | 16.11B | |
| -0.19% | -4.10% | - | - | 16.08B | |
| -0.62% | +2.02% | +2.76% | +14.08% | 13.61B | |
| -3.15% | -4.43% | -4.82% | -37.02% | 12.62B | |
| Average | -0.04% | +0.86% | +59.25% | +85.47% | 27.82B | |
| Weighted average by Cap. | -1.24% | +1.82% | +76.47% | +103.76% |
| 2019 | 2020 | |
|---|---|---|
| Net sales | - | - |
| Net income | -21.21M -15.09M -13.12M -12.24M -11.25M -1.44B -21.58M -144M -56.43M -718M -56.73M -55.48M -2.38B | 4.21M 2.99M 2.6M 2.43M 2.23M 286M 4.28M 28.62M 11.2M 143M 11.26M 11.01M 472M |
| Net Debt | 704K 501K 436K 406K 373K 47.78M 716K 4.79M 1.87M 23.83M 1.88M 1.84M 78.87M | 920K 654K 569K 531K 488K 62.43M 936K 6.25M 2.45M 31.14M 2.46M 2.41M 103M |
Employees
-
